Dino Shaped Chicken Nuggets Caution! Tyson Recalls 30,000 Pounds Voluntarily

Tyson Foods Inc. (NYSE: TSN) has initiated a recall of approximately 29,819 pounds of its novelty chicken products due to concerns over potential contamination. 

Tyson Foods Inc. (NYSE:TSN) has initiated a recall of approximately 29,819 pounds of its novelty chicken products due to concerns over potential contamination. 

The recall specifically targets the brand’s dinosaur-shaped “Fun Nuggets” after reports surfaced of extraneous material—small metal fragments—found within the food items, reported Reuters.

The oversight in product safety was caught by the Food Safety and Inspection Service (FSIS) of the U.S. Department of Agriculture, which also shared news of the recall. The FSIS disclosed that one individual suffered a minor oral injury after consuming the “Fun Nuggets,” with no further reported injuries or illnesses to date.

The recall was announced following a few accounts from buyers who discovered flexible metal pieces in the packages. The Tyson brand’s 29-ounce packages of fully cooked “Fun Nuggets” are the only products implicated in this recall.

According to Tyson Foods, the production of the affected batch occurred in a single day, making the scope of the potential impact more manageable. The affected batch was manufactured at one of the company’s facilities on September 5, 2023.

The product was shipped to distributors in Alabama, California, Illinois, Kentucky, Michigan, Ohio, Tennessee, Virginia, and Wisconsin for further distribution to the retail level.

Price Action: TSN shares closed lower by 1.05% at $47.06 on Friday.

Disclaimer: This content was partially produced with the help of AI tools and was Reviewed And Published By Benzinga Editors.

Photo Via Wikimedia Commons

Total
0
Shares
Related Posts
Read More

Biodexa CEO Issues Shareholder Letter Highlighting Progress In 2023 And Expected Milestones In 2024; Says With The Pipeline Stronger Than It Has Ever Been, We Are Enthusiastic About The Potential For Our Company In 2024 And Beyond

Biodexa Pharmaceuticals PLC("Biodexa" or the "Company")Biodexa CEO Issues Shareholder Letter Highlighting Progress in 2023and Expected Milestones in 2024CARDIFF, United Kingdom, Jan. 22, 2024 (GLOBE NEWSWIRE) – Biodexa

BDRX

Read More

Impel Pharmaceuticals Earlier Announced Streamlining Plan, Including 16% Workforce Reduction, Largely In The R&D Functions, The Company Plans To Reprioritize Spending On Trudhesa (Dihydroergotamine Mesylate) Nasal Spray For Migraine

The plan will halt research and development efforts on INP105 (olanzapine) to address acute agitation and aggression in autism spectrum disorder.  Aligned with this, the Company also announced that Stephen

IMPL